11 insiders reported 53 Form 4 transactions for GENELUX Corp (GNLX) over the past 18 months (most recent 2026-07-02). Recent activity: Smither John W (Director) Sell 12,000 shares, Tyree James L (Director) Buy 28,409 shares, Smither John W (Director) Buy 28,409 shares, Groen Eric (General Counsel) Buy 233,957 shares, Yu Yong (Chief Scientific Officer) Buy 119,318 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Smither John W | Director | Sell | 12,000 | $34,898 |
| 2026-06-18 | Tyree James L | Director | Buy | 28,409 | $0 |
| 2026-06-18 | Smither John W | Director | Buy | 28,409 | $0 |
| 2026-06-18 | Groen Eric | General Counsel | Buy | 233,957 | $0 |
| 2026-06-18 | Yu Yong | Chief Scientific Officer | Buy | 119,318 | $0 |
| 2026-06-18 | Mirabelli Mary | Director | Buy | 28,409 | $0 |
| 2026-06-18 | Zindrick Thomas | President and CEO | Buy | 730,601 | $0 |
| 2026-06-18 | Thomas John | Director | Buy | 28,409 | $0 |
| 2026-06-18 | Cappello Joseph | Chief Technical Officer | Buy | 174,841 | $0 |
| 2026-06-18 | Pulisic Matthew | Chief Financial Officer | Buy | 278,906 | $0 |
| 2026-06-02 | Thomas John | Director | Sell | 10,000 | $29,801 |
| 2026-05-12 | Zindrick Thomas | President and CEO | Sell | 2,798 | $8,226 |
| 2026-05-12 | Yu Yong | Chief Scientific Officer | Sell | 605 | $1,798 |
| 2026-05-12 | Cappello Joseph | Chief Technical Officer | Sell | 605 | $1,799 |
| 2026-05-12 | Smalling Ralph | Head of Regulatory | Sell | 270 | $804 |
| 2026-03-26 | Cappello Joseph | Chief Technical Officer | Sell | 906 | $2,193 |
| 2026-03-26 | Smalling Ralph | Head of Regulatory | Sell | 345 | $835 |
| 2026-03-26 | Smalling Ralph | Head of Regulatory | Sell | 240 | $602 |
| 2026-03-26 | Zindrick Thomas | President and CEO | Sell | 3,582 | $8,668 |
| 2026-03-26 | Yu Yong | SVP, Clinical Development | Sell | 906 | $2,193 |
| 2026-03-03 | Thomas John | Director | Sell | 10,000 | $29,000 |
| 2025-12-11 | Zindrick Thomas | President and CEO | Sell | 4,509 | $24,213 |
| 2025-12-11 | Yu Yong | SVP, Clinical Development | Sell | 973 | $5,225 |
| 2025-12-11 | Zindrick Thomas | President and CEO | Sell | 12,673 | $42,201 |
| 2025-12-11 | Yu Yong | SVP, Clinical Development | Sell | 3,219 | $10,816 |
Source: SEC Form 4 filings · as of 2026-07-02